CE marking have never really been about efficacy.
It's typically been about safety and technical compliance with manufacturing safety.
That's why it has been traditionally the first port of call for new drugs and technologies.
If they are increasing their clinical requirements, BSI should be the ones to guide companies through it.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.030(3.09%) |
Mkt cap ! $14.22M | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.00 | 96.0¢ | $39.65K | 40.44K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 391 | 2 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |